Daxor Co. (NASDAQ:DXR) Sees Large Decline in Short Interest

Daxor Co. (NASDAQ:DXR) was the target of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 12,100 shares, a drop of 8.3% from the January 15th total of 13,200 shares. Based on an average daily trading volume, of 16,500 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.6% of the shares of the stock are short sold.

Daxor Stock Up 0.7 %

Shares of DXR traded up $0.05 during mid-day trading on Monday, hitting $7.18. The company’s stock had a trading volume of 3,233 shares, compared to its average volume of 4,748. The firm has a 50-day simple moving average of $7.96 and a 200 day simple moving average of $8.62. Daxor has a 1-year low of $6.55 and a 1-year high of $10.00.

Hedge Funds Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Renaissance Technologies LLC grew its stake in shares of Daxor Co. (NASDAQ:DXR) by 87.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,821 shares of the company’s stock after buying an additional 13,000 shares during the period. Renaissance Technologies LLC owned 0.57% of Daxor worth $214,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.